Treatment
Fruquintinib clinical trials
We’re tracking 46 recruiting studies that include Fruquintinib, each written for real people, not researchers, below.
Recruiting studies
- NCT07235293RecruitingPhase 2
Testing a new drug combo for advanced colorectal cancer
This trial tests a new combination of two drugs (DSP107 and atezolizumab) compared to another drug (fruquintinib) for people with advanced colorectal cancer that hasn't responded to standard treatments. The goal is to find a more effective treatment option.
Aurora, ColoradoAges 18 years+ - NCT07130903RecruitingPhase 2
Fruquintinib plus special radio waves for advanced colon cancer
This trial tests whether combining fruquintinib (a pill) with low-level radio waves can help people whose metastatic colorectal cancer has stopped responding to or is intolerant of standard treatments. It’s for those who have tried certain chemotherapies and anti-VEGF therapy.
Bay City, MichiganAges 22 years+ - NCT07124858Recruiting
Fruquintinib for advanced colorectal cancer
This study tracks how well fruquintinib works for people with advanced colorectal cancer that has spread. It aims to find factors that predict better outcomes, using blood and tumor samples.
Poitiers, FranceAges 18 years+ - NCT06979908RecruitingPhase 2
A study of fruquintinib plus immunotherapy for advanced colorectal cancer
This trial tests a combination of three drugs (fruquintinib, a PD-1 inhibitor, and chidamide) for people with a specific type of advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
Changchun, JilinAges 18–75 - NCT06980532RecruitingPhase 1/Phase 2
Glumetinib and Fruquintinib for advanced colorectal cancer
This trial tests a combination of two targeted drugs (Glumetinib and Fruquintinib) for people with a specific type of advanced colorectal cancer that has a change in the MET gene (amplification) or too much MET protein. It is for those whose cancer has not responded to at least two prior treatments.
Wuhan, HubeiAges 18 years+ - NCT07042685RecruitingPhase 2
5-FU and Fruquintinib for advanced colorectal cancer
This trial tests a combination of two drugs (5-FU and fruquintinib) in people with advanced colorectal cancer that cannot be removed by surgery or has spread. It is for those who have not had chemotherapy before.
Houston, TexasAges 18 years+ - NCT07011576RecruitingPhase 2
Fruquintinib plus FOLFIRI for second-line metastatic colorectal cancer
This trial tests a combination of two drugs, fruquintinib and FOLFIRI chemotherapy, as a second treatment option for people with metastatic colorectal cancer. It is designed for patients who have already received one prior treatment containing oxaliplatin, fluoropyrimidine, and bevacizumab.
Denver, ColoradoAges 18 years+ - NCT05771181RecruitingPhase 2
Test vitamin E plus two cancer drugs for metastatic colon cancer
This trial tests whether adding vitamin E to two cancer medicines (fruityquintinib and tislelizumab) can work better in people with metastatic colorectal cancer that is mismatch-repair stable (MSS). It may help if your cancer has grown despite standard treatment, and you can meet the study’s safety and blood/organ requirements.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06856837RecruitingPhase 2
Fruquintinib and Tislelizumab for advanced colorectal cancer
This trial tests a combination of two drugs, fruquintinib and tislelizumab, for people with a specific type of advanced colorectal cancer that has not spread to the liver. It is for those whose cancer is stable in certain DNA repair systems (MSS/pMMR) and who have already tried other treatments.
LinzAges 18 years+ - NCT06329973RecruitingPhase 1/Phase 2
Fruquintinib, sintilimab, and chemo for stomach cancer
This trial tests a combination of three drugs (fruquintinib, sintilimab, and CAPEOX chemotherapy) as a first treatment for advanced stomach or gastroesophageal cancer. The goal is to see if this combination helps slow or shrink the tumor.
Zhengzhou, HenanAges 18–75 - NCT06441565RecruitingPhase 2/Phase 3
Fruquintinib with or without liver-directed chemo for advanced colorectal cancer
This trial tests a drug called fruquintinib, given alone or with a chemotherapy infusion directly into your liver, for people whose colorectal cancer has spread to the liver and has stopped responding to standard treatments. It aims to find a new option for patients with limited cancer outside the liver.
Guangzhou, GuangdongAges 18–75 - NCT06562543RecruitingPhase 4
Fruquintinib for advanced colorectal cancer in minority populations
This trial tests a medication called fruquintinib (an oral pill) for people with advanced colorectal cancer that has not responded to prior treatments. It is specifically looking for participants who identify as Black or African American and/or Hispanic or Latino to help understand how the drug works in these groups.
Birmingham, AlabamaAges 18 years+ - NCT06417892Recruiting
Fruquintinib combo with or without immunotherapy for stomach cancer
This trial tests a combination of two drugs (fruquintinib and albumin-paclitaxel) with or without an immunotherapy drug (PD-1 antibody) as a second-line treatment for advanced stomach cancer. It aims to see if adding immunotherapy improves outcomes for people who have already received immunotherapy before.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06356584RecruitingPhase 2
A drug combination with or without radiation for advanced colorectal cancer
This trial tests a new drug combo (fruquintinib and sintilimab) with or without radiation for people with colorectal cancer that has spread to the liver and has not responded to earlier treatments.
Jinan, ShandongAges 18–75 - NCT05954429RecruitingPhase 2
Study of fruquintinib plus immunotherapy after standard CRC treatment
This trial studies fruquintinib combined with serplulimab (an immune therapy) for advanced colorectal cancer that has spread and is no longer responding to standard treatments. It may help by slowing the cancer’s growth and improving outcomes after the usual options have been tried.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07623174Recruiting
Fruquintinib for Advanced Colorectal Cancer in Poland
This study follows adults in Poland who are receiving fruquintinib, a targeted cancer medicine, for advanced colorectal cancer that has spread. You would be enrolled if your doctor is already planning to give you fruquintinib as a later-line treatment after other therapies have stopped working.
Poznan, Greater Poland VoivodeshipAges 18 years+ - NCT07003022RecruitingPhase 2
Two-drug combo for advanced colorectal cancer
This trial tests a combination of two drugs (cadonilimab and an anti-angiogenic agent) for advanced colorectal cancer that has a specific genetic feature (dMMR or MSI-H). It aims to find a new treatment option that might work better than current therapies.
Shanghai, ChinaAges 18–80 - NCT06787105Recruiting
Fruquintinib for advanced colorectal cancer
This trial tests a drug called fruquintinib for people with advanced colorectal cancer that has spread. It is for patients who have already tried several standard treatments and need a new option.
Biberach, Baden-WurttembergAges 18 years+ - NCT05571644RecruitingPhase 2
Study compares two pre-surgery treatments for locally advanced rectal cancer
This Phase 2 trial tests whether a newer combination chemotherapy plus an immunotherapy medicine (cadonilimab/AK104) works better than standard chemotherapy before surgery for locally advanced colorectal cancer. The goal is to shrink the tumor and improve how well treatment works after surgery.
Guangzhou, GuangdongAges 18–70 - NCT06497985RecruitingPhase 3
New drug combo for advanced colorectal cancer
This trial tests a combination of three drugs—tucidinostat, sintilimab, and bevacizumab—for people with a specific type of advanced colorectal cancer (MSS or pMMR) that has gotten worse after standard treatments. The goal is to see if this new mix can help shrink or slow the tumor.
Guangzhou, GuangdongAges 18–75 - NCT05867420RecruitingPhase 1/Phase 2
ASKG915 for advanced solid tumors that stopped responding
This early-stage study tests ASKG915, a new treatment, for people with advanced solid cancers that are no longer responding to standard care (or don’t have standard options). If you may qualify, you’d be screened with recent health tests to check safety and eligibility, and then receive the study drug.
New York, New YorkAges 18 years+ - NCT05405595RecruitingPhase 1/Phase 2
Study drug with pembrolizumab for advanced solid tumors
This early-stage trial tests a new investigational drug (ADG126) combined with pembrolizumab in people with advanced or metastatic solid tumors. It aims to find a safe dose and see whether the combination can shrink tumors.
Scottsdale, ArizonaAges 18 years+
Common questions
- Are there clinical trials studying Fruquintinib?
- Yes. Clin2 currently lists 46 recruiting studies that include Fruquintinib, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Fruquintinib trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Fruquintinib an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Fruquintinib or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.